1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Teijin Limited

Teijin Limited

TINLF
Teijin LimitedUS flagOther OTC
9.51
USD
- -
- -
1.83BMarket Cap
Teijin Limited
TINLF
(Other OTC)

Recent

price

9.51

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
4,144.45
4,340.3
3,790.16
3,990.52
3,999.86
4,022.34
3,769.25
4,238.7
4,583.07
4,450.37
4,357.81
4,821.82
5,299.29
4,990.33
5,219.43
- -
2,733.62
Revenue per Share
127.95
60.85
-148.06
42.51
-41.14
158.15
254.91
231.26
232.39
131.63
-34.71
120.58
-92.04
-60.85
147.15
- -
57.86
Basic EPS, GAAP
262.58
113.65
155.58
28.06
239.83
233.71
195.45
172.88
113.32
124.55
243.82
-577.02
-13.78
26.21
43.69
- -
- -
Free Cash Flow per Basic Share
19.98
30
25.01
20
19.99
25
44.99
59.92
60.28
69.99
55
52.5
54.99
27.5
40
- -
- -
Dividend per Share
1,047.73
1,078.29
905.44
928.77
875.18
1,008.16
1,217.67
1,392.18
1,584.22
1,662.29
1,571.38
1,635.81
1,444.77
1,434.07
1,575.78
- -
1,144.88
Book Value per Share
1,219.89
1,267.62
1,313.61
1,376.87
1,439.87
1,514.62
1,437.9
1,766.05
1,844.93
1,829.8
1,833.15
1,426.99
1,363.73
1,492
1,789.33
- -
1,288.88
Tangible Book Value per Share
197
197
197
197
197
197
197
197
194
192
192
192
192
192
193
- -
193
Basic Weighted Avg Shares
815,655
854,370
745,712
784,424
786,171
790,748
741,291
834,986
888,589
853,746
836,512
926,054
1,018,751
960,459
1,005,471
873,190
526,269
Sales/Revenue/Turnover
5.95
3.98
1.66
2.3
4.97
8.49
7.62
8.36
6.75
6.58
6.57
4.77
1.26
-0.51
-7.14
-8.1
0.68
Operating Margin (%)
56,410
52,303
46,876
45,663
43,030
38,893
39,331
45,655
47,551
50,950
51,840
68,816
74,918
78,032
71,026
- -
- -
Depreciation Expense
25,182
11,979
-29,130
8,356
-8,086
31,090
50,133
45,556
45,057
25,252
-6,662
23,158
-17,695
-11,712
28,347
-88,003
11,140
Net Income, GAAP
36.34
52.9
- -
54.46
- -
35.89
- -
30.63
22.47
35.08
145.06
41.07
- -
52.07
- -
- -
34.63
Effective Tax Rate (%)
3.09
1.4
-3.91
1.07
-1.03
3.93
6.76
5.46
5.07
2.96
-0.8
2.5
-1.74
-1.22
2.82
-10.08
2.12
Profit Margin (%)
92,124
83,838
82,974
116,246
164,449
202,308
187,182
201,673
223,649
217,683
224,526
220,240
187,294
184,924
268,921
226,165
209,693
Working Capital
168,870
132,191
132,247
166,401
208,705
218,793
265,540
242,216
240,622
247,801
245,132
333,935
329,082
295,385
254,188
199,418
289,635
LT Debt
307,698
312,216
292,126
300,111
303,632
314,410
351,828
408,237
427,213
411,410
430,366
464,813
416,350
436,759
438,541
368,632
379,913
Total Equity
5.16
2.77
- -
1.44
- -
6.94
- -
6.51
5.97
4.56
-3.07
2.94
- -
0.66
- -
- -
0.24
Return on Invested Capital (%)
4.87
2.67
- -
2.46
- -
6.85
- -
7.29
6.97
3.69
-1.46
2.92
- -
1.54
- -
- -
1.6
Return on Capital (%)
12.91
5.73
-14.92
4.63
-4.56
16.8
22.91
17.74
15.5
8.07
-2.15
7.52
-5.98
-4.23
9.78
-34.25
4.43
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
221,552
- -
257,418
LT Borrowings
270,378
- -
268,031
LT Finance Leases
25,007
- -
21,604
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
193
- -
193
Market Capitalization
345,141
303,404
270,637

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
625,622
- -
660,349
Cash, Cash Equivalents & STI
137,754
- -
121,416
Accounts Receivable, Net
222,629
- -
196,130
Inventories
233,974
- -
249,104
Total Current Liabilities
440,698
- -
450,656
Payables & Accruals
- -
- -
- -
ST Debt
221,552
- -
257,418
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.04%
-2.61%
-15.94%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-152.96%
-282.06%
-410.45%
Sales/Revenue/Turnover
1.34%
1.3%
-13.16%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
244,841
261,663
253,095
273,174
960,459
2025
- -
- -
- -
- -
1,005,471
2026
- -
- -
- -
- -
873,190

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9.66
- -
- -
- -
-60.85
2025
- -
- -
- -
- -
147.15
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
27.5
2025
- -
- -
- -
- -
40
2026
- -
- -
- -
- -
- -
Similar Companies
Aarti Surfactants Limited (AARTISURF.BO)
Tidewater Renewables Ltd. (TDWRF)
PT Indo Komoditi Korpora Tbk (INCF.JK)
Hydromer, Inc. (HYDI)
Nikhil Adhesives Limited (NIKHILAD.BO)
Multibase India Limited (MULTIBASE.BO)
Business
Teijin Limited (TINLF) manufactures and markets advanced fibers, composites, performance polymers, films, healthcare products, and IT solutions worldwide. The company produces aramid fibers such as Twaron, carbon fibers and composites for aerospace and automotive applications, high-performance polyethylene including Endumax branded UHMWPE, high-performance polyester and PEN fibers, artificial leather, flame-resistant fibers, polycarbonate resin, polyphenylene sulfide resin, PET and PEN films and sheets, polyester fibers, resin and plastic processing products, and fibers and products converting solutions; it also offers pharmaceuticals, medical equipment, and home healthcare devices targeting quality-of-life improvements. Teijin operates through materials and healthcare business fields, serving industries including automotive, aerospace, electronics, textiles, civil engineering, and medical sectors across Japan, North America, Europe, Asia, and other regions with 153 group companies and approximately 20,000 employees. Founded in 1918 and headquartered in Tokyo, Japan, the company maintains a global footprint with key facilities in the United States, Europe, and Asia. Recent developments include the March 2025 divestiture of Teijin Automotive Technologies North America to AURELIUS Private Equity, enhancing focus on core competencies; a December 2025 agreement with Asahi Kasei to integrate Teijin Frontier Co., Ltd., with Asahi Kasei Advance Corporation into a joint venture effective October 2026, where Teijin holds an 80% stake to strengthen textile and functional materials platforms; and a strategic collaboration with Cell Therapies to expand access to advanced cell and gene therapies in Japan and the Asia Pacific region.